A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1
- PMID: 1736810
- DOI: 10.1016/0166-3542(92)90090-r
A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1
Abstract
Sequences from the gag, pol and rev regions of the RF strain of HIV-1 (HIV-1RF) were chosen as targets for antisense phosphorothioate oligodeoxynucleotides (S-oligos). These sequences were the p18/p24 junction in gag, the active site of HIV protease in pol; a sequence from the first exon of the rev gene and S-oligodeoxycytidylic acid controls. Compounds were tested against HIV-1 in both acutely and chronically infected cells. The results show that these phosphorothioate analogues tested in acutely infected cells were active in the 0.1-2 microM range, were dependent on chain length but had no sequence specificity. To study the mechanism of action, the time of addition of S-oligos to acutely infected cells was delayed for up to 48 h post-infection. It was found that antiviral activity was lost when compounds were added to the cultures later than 10 h post-infection. With chronically infected cells only the antisense rev sequence showed activity at 30 microM and neither of the gag or pol antisense sequences has a significant effect on HIV replication at 50 microM. These results are consistent with previous in vitro studies which demonstrate that antisense S-oligodeoxynucleotides have several modes of action.
Similar articles
-
Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity.Biochem Biophys Res Commun. 1996 Nov 12;228(2):623-31. doi: 10.1006/bbrc.1996.1707. Biochem Biophys Res Commun. 1996. PMID: 8920960
-
Inhibition of human immunodeficiency virus type 1 (HIV) gag gene expression by an antisense oligodeoxynucleotide phosphorothioate.Leukemia. 1995 Oct;9 Suppl 1:S86-8. Leukemia. 1995. PMID: 7475322
-
Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.Proc Natl Acad Sci U S A. 1993 May 1;90(9):3860-4. doi: 10.1073/pnas.90.9.3860. Proc Natl Acad Sci U S A. 1993. PMID: 8483903 Free PMC article.
-
Antisense oligonucleotides as therapeutic agents--is the bullet really magical?Science. 1993 Aug 20;261(5124):1004-12. doi: 10.1126/science.8351515. Science. 1993. PMID: 8351515 Review.
-
Oligodeoxynucleotides as antisense inhibitors of gene expression.Prog Nucleic Acid Res Mol Biol. 1992;42:79-126. doi: 10.1016/s0079-6603(08)60574-7. Prog Nucleic Acid Res Mol Biol. 1992. PMID: 1574591 Review. No abstract available.
Cited by
-
Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.Nucleic Acids Res. 1994 Oct 11;22(20):4307-14. doi: 10.1093/nar/22.20.4307. Nucleic Acids Res. 1994. PMID: 7524038 Free PMC article.
-
Gene therapy for infectious diseases.Clin Microbiol Rev. 1998 Jan;11(1):42-56. doi: 10.1128/CMR.11.1.42. Clin Microbiol Rev. 1998. PMID: 9457428 Free PMC article. Review.
-
Engineering T Cells to Functionally Cure HIV-1 Infection.Mol Ther. 2015 Jul;23(7):1149-1159. doi: 10.1038/mt.2015.70. Epub 2015 Apr 21. Mol Ther. 2015. PMID: 25896251 Free PMC article. Review.
-
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.J Virol. 2000 May;74(10):4621-33. doi: 10.1128/jvi.74.10.4621-4633.2000. J Virol. 2000. PMID: 10775598 Free PMC article.
-
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.J Virol. 2002 Apr;76(8):3881-91. doi: 10.1128/jvi.76.8.3881-3891.2002. J Virol. 2002. PMID: 11907228 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources